South Korea · Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 278.10 billion. The enterprise value is 300.23 billion.
| Market Cap | 278.10B |
| Enterprise Value | 300.23B |
Important Dates
The last earnings date was Wednesday, August 19, 2026.
| Earnings Date | Aug 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 14.26 million shares outstanding. The number of shares has increased by 5.84% in one year.
| Current Share Class | 14.26M |
| Shares Outstanding | 14.26M |
| Shares Change (YoY) | +5.84% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 24.56% |
| Owned by Institutions (%) | 15.47% |
| Float | 9.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 12.43 |
| PS Ratio | 2.23 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 3.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.31 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.29 |
| Interest Coverage | -10.46 |
Financial Efficiency
Return on equity (ROE) is -29.22% and return on invested capital (ROIC) is -18.47%.
| Return on Equity (ROE) | -29.22% |
| Return on Assets (ROA) | -8.15% |
| Return on Invested Capital (ROIC) | -18.47% |
| Return on Capital Employed (ROCE) | -20.58% |
| Weighted Average Cost of Capital (WACC) | 13.61% |
| Revenue Per Employee | 417.43M |
| Profits Per Employee | -65.77M |
| Employee Count | 299 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.75 |
Taxes
In the past 12 months, HansBiomed has paid 2.30 billion in taxes.
| Income Tax | 2.30B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +149.68% in the last 52 weeks. The beta is 1.99, so HansBiomed's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | +149.68% |
| 50-Day Moving Average | 22,589.00 |
| 200-Day Moving Average | 30,701.00 |
| Relative Strength Index (RSI) | 42.94 |
| Average Volume (20 Days) | 132,915 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 124.81 billion and -19.66 billion in losses. Loss per share was -1,432.07.
| Revenue | 124.81B |
| Gross Profit | 74.65B |
| Operating Income | -18.35B |
| Pretax Income | -18.19B |
| Net Income | -19.66B |
| EBITDA | -13.78B |
| EBIT | -18.35B |
| Loss Per Share | -1,432.07 |
Balance Sheet
The company has 19.62 billion in cash and 42.14 billion in debt, with a net cash position of -22.52 billion or -1,579.18 per share.
| Cash & Cash Equivalents | 19.62B |
| Total Debt | 42.14B |
| Net Cash | -22.52B |
| Net Cash Per Share | -1,579.18 |
| Equity (Book Value) | 78.00B |
| Book Value Per Share | 5,496.50 |
| Working Capital | 19.06B |
Cash Flow
In the last 12 months, operating cash flow was -15.64 billion and capital expenditures -2.78 billion, giving a free cash flow of -18.42 billion.
| Operating Cash Flow | -15.64B |
| Capital Expenditures | -2.78B |
| Depreciation & Amortization | 4.57B |
| Net Borrowing | -2.57B |
| Free Cash Flow | -18.42B |
| FCF Per Share | -1,291.68 |
Margins
Gross margin is 59.81%, with operating and profit margins of -14.70% and -15.76%.
| Gross Margin | 59.81% |
| Operating Margin | -14.70% |
| Pretax Margin | -14.57% |
| Profit Margin | -15.76% |
| EBITDA Margin | -11.04% |
| EBIT Margin | -14.70% |
| FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.84% |
| Shareholder Yield | -5.84% |
| Earnings Yield | -7.07% |
| FCF Yield | -6.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 3.14 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.14 |
| Piotroski F-Score | 3 |